Management of infection in cancer patients

Studies of the EORTC International Antimicrobial Therapy Group (IATG)

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Infection remains an important cause of morbidity and mortality in cancer patients, especially those undergoing chemotherapy for haematological malignancies. The practice of instituting an empirical broad-spectrum antibiotic therapy as soon as possible after the onset of fever has substantially reduced the clinical impact of this complication. In the last 25 years, the International Antimicrobial Therapy Group of the European Organisation for Research and Treatment of Cancer (EORTC-IATG) have published nearly 30 articles and a number of abstracts on several facets of the epidemiology and management of infection in cancer patients. With a progressive methodological refinement, the EORTC-IATG trials have established the standard for the management of febrile neutropenia, both by setting methodologies and definitions and by testing several antibiotic regimens that are active and effective for this indication. With the aim of supporting a more rational use of antibiotics in cancer patients, the most recent trials have dealt with the management of low risk patients, showing the safety and feasibility of oral therapy.

Original languageEnglish
JournalEuropean Journal of Cancer
Volume38
Issue numberSUPPL. 4
Publication statusPublished - 2002

Fingerprint

Group Psychotherapy
Anti-Bacterial Agents
Infection
Febrile Neutropenia
Neoplasms
Risk Management
Hematologic Neoplasms
Patient Safety
Epidemiology
Fever
Morbidity
Drug Therapy
Mortality
Therapeutics

Keywords

  • Cancer
  • Clinical trial
  • Fever
  • Infection
  • Neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

@article{4d2bb0622b964d52a5043226705e1ab2,
title = "Management of infection in cancer patients: Studies of the EORTC International Antimicrobial Therapy Group (IATG)",
abstract = "Infection remains an important cause of morbidity and mortality in cancer patients, especially those undergoing chemotherapy for haematological malignancies. The practice of instituting an empirical broad-spectrum antibiotic therapy as soon as possible after the onset of fever has substantially reduced the clinical impact of this complication. In the last 25 years, the International Antimicrobial Therapy Group of the European Organisation for Research and Treatment of Cancer (EORTC-IATG) have published nearly 30 articles and a number of abstracts on several facets of the epidemiology and management of infection in cancer patients. With a progressive methodological refinement, the EORTC-IATG trials have established the standard for the management of febrile neutropenia, both by setting methodologies and definitions and by testing several antibiotic regimens that are active and effective for this indication. With the aim of supporting a more rational use of antibiotics in cancer patients, the most recent trials have dealt with the management of low risk patients, showing the safety and feasibility of oral therapy.",
keywords = "Cancer, Clinical trial, Fever, Infection, Neutropenia",
author = "C. Viscoli",
year = "2002",
language = "English",
volume = "38",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Management of infection in cancer patients

T2 - Studies of the EORTC International Antimicrobial Therapy Group (IATG)

AU - Viscoli, C.

PY - 2002

Y1 - 2002

N2 - Infection remains an important cause of morbidity and mortality in cancer patients, especially those undergoing chemotherapy for haematological malignancies. The practice of instituting an empirical broad-spectrum antibiotic therapy as soon as possible after the onset of fever has substantially reduced the clinical impact of this complication. In the last 25 years, the International Antimicrobial Therapy Group of the European Organisation for Research and Treatment of Cancer (EORTC-IATG) have published nearly 30 articles and a number of abstracts on several facets of the epidemiology and management of infection in cancer patients. With a progressive methodological refinement, the EORTC-IATG trials have established the standard for the management of febrile neutropenia, both by setting methodologies and definitions and by testing several antibiotic regimens that are active and effective for this indication. With the aim of supporting a more rational use of antibiotics in cancer patients, the most recent trials have dealt with the management of low risk patients, showing the safety and feasibility of oral therapy.

AB - Infection remains an important cause of morbidity and mortality in cancer patients, especially those undergoing chemotherapy for haematological malignancies. The practice of instituting an empirical broad-spectrum antibiotic therapy as soon as possible after the onset of fever has substantially reduced the clinical impact of this complication. In the last 25 years, the International Antimicrobial Therapy Group of the European Organisation for Research and Treatment of Cancer (EORTC-IATG) have published nearly 30 articles and a number of abstracts on several facets of the epidemiology and management of infection in cancer patients. With a progressive methodological refinement, the EORTC-IATG trials have established the standard for the management of febrile neutropenia, both by setting methodologies and definitions and by testing several antibiotic regimens that are active and effective for this indication. With the aim of supporting a more rational use of antibiotics in cancer patients, the most recent trials have dealt with the management of low risk patients, showing the safety and feasibility of oral therapy.

KW - Cancer

KW - Clinical trial

KW - Fever

KW - Infection

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0036181802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036181802&partnerID=8YFLogxK

M3 - Article

VL - 38

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - SUPPL. 4

ER -